Business
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline prog
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Press release – No. 2 / 2026","length":28,"tagName":"p"},{"type":"text","content":"Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy","length":146,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidates","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Agreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030","length":191,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":390,"olType":false},{"type":"text","content":"Copenhagen, Denmark, January 9, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces an agreement with DCAI, an AI infrastructure company which operates Gefion, Denmark’s supercomputer, to strengthen and accelerate drug discovery.","length":323,"tagName":"p"},{"type":"text","content":"Working with DCAI, Zealand Pharma will be able to integrate enterprise-scale artificial intelligence into its drug discovery and development workflows, generating proprietary insights that further enhance the quality and efficiency of medicine creation as the Company executes its Metabolic Frontier 2030 strategy.","length":314,"tagName":"p"},{"type":"text","content":"Gefion’s state-of-the-art infrastructure provides Zealand Pharma with scalable, flexible computational power tailored to the specific requirements of each research project. With more than 1,500 NVIDIA GPUs...